Product
Hyperbaric Oxygen Therapy + Camrelizumab
1 clinical trial
3 indications
Indication
Combination ImmunotherapyIndication
Hepatocellular Carcinoma Non-ResectableIndication
Hyperbaric Oxygen TherapyClinical trial
A Single-center, Single-arm, Non-randomized Clinical Study to Evaluate the Efficacy and Safety of Hyperbaric Oxygen Therapy Plus Camrelizumab as a Second-line Treatment in Advanced/Metastatic Hepatocellular CarcinomaStatus: Recruiting, Estimated PCD: 2024-12-31